As women with EC with MMR deficiency or MSI (hypermutated) may benefit from immunotherapy, consideration should be given for MMR deficiency testing for women with EC who are candidates for chemotherapy. This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.